Patent 11033626 was granted and assigned to TherapeuticsMD on June, 2021 by the United States Patent and Trademark Office.
This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.